Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as an oral tablet for oral use. It is used for the medical termination of intrauterine pregnancy up to 10 weeks gestation. GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifegyne is a progesterone receptor antagonist used in early pregnancy management. - Intrauterine pregnancy up to 10 weeks: induces medical abortion by disrupting the uterine lining. - Early pregnancy termination: facilitates uterine evacuation when combined with prostaglandins. - Clinical pregnancy management: provides a pharmacologic option for terminating early gestation in approved settings.

Mifegyne may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vaginal bleeding: variable intensity, often heavier than a normal period. - Abdominal cramping: uterine contractions causing discomfort. - Diarrhea: occasional loose stools. - Fatigue: general tiredness during the process. - Headache: transient mild headaches.

Serious or Rare Side Effects: - Heavy bleeding: excessive hemorrhage requiring medical attention. - Infection: signs of fever or uterine infection. - Allergic reaction: rash, itching, or swelling. - Liver injury: elevated enzymes or jaundice. - Severe abdominal pain: may indicate complications. - Uterine rupture: extremely rare but critical emergency.

Mifegyne requires careful clinical assessment before use. - Confirm gestational age: ensure pregnancy is ≤10 weeks. - Baseline labs: check hemoglobin and Rh status. - Contraindications review: avoid in chronic adrenal failure or anticoagulant therapy. - Patient counseling: explain procedure, expected bleeding, and follow‑up. - Store at ambient temperature: keep in original packaging, protect from moisture.

Mifegyne can interact with other medications, affecting efficacy or safety.

Major Interactions (Avoid): - Rifampin: induces metabolism, reducing effectiveness. - Strong CYP3A4 inducers (e.g., carbamazepine): may lower drug levels. - Antifungal azoles (e.g., ketoconazole): can increase serum concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may heighten bleeding risk. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Hormonal contraceptives: assess for reduced efficacy.